RecruitingPHASE2, PHASE3NCT02265770
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
Studying Ependymoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Leon Berard
- Principal Investigator
- Pierre LEBLOND, MDIHOP
- Intervention
- 16 weeks of VEC + CDDP(drug)
- Enrollment
- 536 enrolled
- Eligibility
- 22 years · All sexes
- Timeline
- 2015 – 2031
Study locations (30)
- Medical University of Graz-Department of Pediatrics and Adolescent Medicine, Graz, Austria
- CHR de la CITADELLE, Liège, Belgium
- University Hospital Brno, Brno, Czechia
- Aarhus University Hospital, Aarhus, Denmark
- CHRU STRASBOURG - Hôpital de Hautepierre, Strasbourg, Bas-Rhin, France
- AP-HM - Hôpital d'Enfants de La Timone, Marseille, Bouches-du-Rhône, France
- CHU Dijon - Hôpital des Enfants, Dijon, Côte d'Or, France
- CHRU BESANCON - Hôpital Jean Minjoz, Besançon, Doubs, France
- CHRU BREST - Hôpital Morvan, Brest, Finistère, France
- CHU de Bordeaux-Hôpital des enfants Pellegrin, Bordeaux, Gironde, France
- CHU de TOULOUSE - Hôpital des Enfants, Toulouse, Haute-Garonne, France
- CHRU MONTPELLIER - Hôpital Arnaud de Villeneuve, Montpellier, Herault, France
- CHU de RENNES - Hôpital Sud, Rennes, Ille-et-Vilaine, France
- CHRU Tours - Hôpital Clocheville, Tours, Indre-et-Loire, France
- CHU GRENOBLE - Hôpital Couple-Enfant, La Tronche, Isère, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02265770 on ClinicalTrials.govOther trials for Ependymoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1NCT04903080HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With EpendymomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT04743661131I-Omburtamab, in Recurrent Medulloblastoma and EpendymomaPediatric Brain Tumor Consortium
- RECRUITINGPHASE1NCT05106296Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerTheodore S. Johnson
- RECRUITINGNCT05151718Multiomic Approach to Radioresistance of Ependymomas in Children and AdolescentsInstitut Claudius Regaud
- ACTIVE NOT RECRUITINGPHASE1NCT04661384Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or MedulloblastomaCity of Hope Medical Center
- ACTIVE NOT RECRUITINGPHASE1NCT02774421Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent EpendymomaUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGPHASE2NCT02125786A Trial of Surgery and Fractionated Re-Irradiation for Recurrent EpendymomaSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGNCT00683319Observing Young Patients With Ependymoma Undergoing Standard Combination ChemotherapyChildren's Cancer and Leukaemia Group